Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)
This program is supported by Abbvie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, Gilead Sciences Inc, Pharmacyclics LLC, An AbbVie Company and Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hilton Orlando
, Orange Ballroom
This activity, the first of a 2-part series, will attempt to address many of the most common practical issues encountered by clinicians managing patients with non-Hodgkin lymphomas as well as chronic lymphocytic leukemia (CLL). To accomplish this goal, prior to the event RTP will recruit 6 general hematologic oncologists to serve as the project’s Planning Committee. These individuals will participate in a closed planning session at RTP headquarters during which a number of key questions, issues and challenging cases from their practices will be discussed. With this information providing the basis for the agenda, the meeting, which will feature 6 renowned lymphoma/CLL investigators serving as the faculty, will employ a blend of short didactic presentations, interactive audience polling using networked iPads and extensive moderated panel discussion to provide perspectives on new and emerging research and address many of the real-world concerns voiced by the Planning Committee members. A video-recorded capture of the program will be distributed as an enduring CME resource to deliver the valuable and practical information that emerges to a larger worldwide audience.
Chair:
Neil Love
, MD, Research To Practice, Miami,
FL
Speakers:
Jeremy S. Abramson
, MD, MMSc
, Massachusetts General Hospital Cancer Center
, Boston,
MA
Bruce D. Cheson
, MD
, Georgetown University Hospital
, Washington,
DC
Professor John G. Gribben
, MD, DSc
, Barts Cancer Institute, Queen Mary University of London
, London,
United Kingdom
Brad S. Kahl
, MD
, Washington University
, St Louis,
MO
Loretta J. Nastoupil
, MD
, The University of Texas MD Anderson Cancer Center
, Houston,
TX
Laurie H Sehn
, MD
, British Columbia Cancer Agency
, Vancouver,
BC, Canada
Contact:
Sylvia Eriksen
, Research To Practice
Registration:
http://www.researchtopractice.com/Meetings/FSS2019
Advances in Hemophilia A: Expert Guidance and Practical Case Discussions
This program is supported by Genentech
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Regency O-Q
This interactive symposium will feature guidance and perspective on expert strategies and therapeutic decisions for patients with hemophilia A. New insights include a look ahead at new data and promising agents that may soon change practice.
Renowned hemophilia experts— Guy Young, MD; Stacy Croteau, MD, MMS; Michael Callaghan, MD; and Cindy Leissinger, MD—will discuss the evidence behind current best practice management strategies, both with and without inhibitors, for patients with hemophilia A requiring prophylaxis.
The program will include patient case challenges and reflection on considerations that impact therapeutic decisions. Recent clinical trial data and ongoing trials of novel therapeutic approaches will be presented, including antithrombin inhibitor, anti-TFPI antibodies, and gene therapy, with a focus on how these agents may affect management strategies for patients with hemophilia A in the near future.
Throughout the symposium, attendees will interact with experts through interactive case challenges and polling questions, as well as by texting questions directly to the panel for their consideration.
Discussion topics include:
- Current clinical progress/unmet needs in hemophilia A
-New developments in factor and nonfactor replacement strategies
-Implementing an individualized care approach
-Clinical challenges in applying new evidence to practice
-Review of rationale/efficacy and safety data for emerging therapies and ongoing clinical trials
Chair:
Guy Young
, MD, Children’s Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles,
CA
Speakers:
Michael Callaghan
, MD
, Wayne State University
, Detroit,
MI
Stacy E. Croteau
, Children's Hospital Boston
, Boston,
MA
Cindy A. Leissinger
, MD
, Tulane University School of Medicine
, New Orleans,
LA
Contact:
For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com
Registration:
http://www.clinicaloptions.com/2019OrlandoHemophilia
Advancing Science in Sickle Cell Disease: Implications for the Future of Care
This program is supported by Novartis
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hilton Orlando
, Orlando Ballroom 1
Sickle cell disease (SCD) is a debilitating, inherited condition that affects about 100,000 individuals in the United States. While it is a molecularly well-characterized disease, there are few treatments available and less than one-third of eligible patients receive standard of care. Fortunately, recent years have brought an explosion in therapeutic advances regarding the management of patients with SCD, including, but not limited to gene therapy, novel drug targets, and new clinically meaningful endpoints. Moreover, an increased understanding of disease state and phenotypes is leading to evolving management recommendations. With these advances, providers will require education by global leading experts on these advances and implications for clinical practice.
Chair:
Kenneth I. Ataga
, MBBS, University of Tennessee Health Science Center at Memphis, Memphis,
TN
Speakers:
Jo Howard
, MB, BChir
, Guy's and St. Thomas' NHS Foundation Trust
, London,
United Kingdom
Julie Kanter
, MD
, Director of the UAB Adult Sickle Cell Clinic Associate Professor in the Division of Hematology and Oncology
, Birmingham,
AL
Mark C. Walters
, MD
, UCSF Benioff Children's Hospital
, Oakland,
CA
Contact:
Contact Us
, Vindico Medical Education
Registration:
VindicoCME120619pm.eventbrite.com
Approaches To Achieve the Best Possible Outcomes in Myeloma
This program is supported by Celgene Corporation, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Karyopharm Therapeutics Inc., Oncopeptides, Takeda Oncology and The Binding Site
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Windermere Ballroom
Attendees of this annual International Myeloma Foundation/Clinical Care Options co-sponsored symposium can expect to gain practical insights from a panel of experts as they discuss new therapeutic advances along with their personal approaches for myeloma care. The international panel will focus on evolving worldwide standards of care and will also provide their perspectives on promising agents that may soon change practice.
Brian G.M. Durie, MD; Shaji Kumar, MD; Thomas G. Martin, MD; Philippe Moreau, MD; S. Vincent Rajkumar, MD; and Jesús F. San-Miguel, MD, PhD will debate clinical questions, discuss available evidence and challenges that impact therapeutic decisions, and then share their individual treatment recommendations for each case. Throughout the symposium, participants will be able to vote on case scenarios and directly interact with the panel in a dynamic question and answer format. Discussion topics include:
- Diagnosis and Risk Stratification of Plasma Cell Disorders: To Treat or Not to Treat
- Making Upfront Therapy Decisions: Advances in Induction, Autologous Transplantation, Consolidation, and Maintenance Therapy
- The Current Therapeutic Landscape for Relapsed or Refractory MM: Which Combinations to Use and When?
- Future Directions: New and Promising Treatments for MM
Review of 2020 Treatment Algorithm for Multiple Myeloma
Chair:
Brian G.M. Durie
, MD, Cedars Sinai Cancer Center, Los Angeles,
CA
Speakers:
Shaji K. Kumar
, MD
, Mayo Clinic
, Rochester,
MN
Thomas G. Martin III
, MD
, University of California, San Francisco
, San Francisco,
CA
Philippe Moreau
, MD
, University Hospital Hôtel-Dieu
, Nantes,
France
S. Vincent Rajkumar
, MD
, Mayo Clinic
, Rochester,
MN
Jesus San-Miguel
, MD,PhD
, Clínica Universidad De Navarra
, Pamplona,
Spain
Contact:
For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com
Registration:
https://www.clinicaloptions.com/2019OrlandoMM
Aware of the Rare: Diagnosing and Treating Immune-Mediated Hematologic Disorders
This program is supported by Alexion Pharmaceuticals, Inc., Rigel Pharmaceuticals, and Sanofi Genzyme
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Regency T-V
A panel of expert hematologists will review the challenges, opportunities, and key advances in the diagnosis and treatment of rare, non-malignant hematologic conditions such as ITP, aTTP, AIHA, aHUS, and PNH. Using a roundtable format, the faculty will review key data for established, newer, and emerging therapies for these distinct disorders. Case-based presentations will drive discussions focused on assessing the strengths and limitations of available therapies, evaluate how different therapies may be used in patient care to improve outcomes, and highlight key considerations when developing individualized care strategies. Interactive gaming through mobile devices will further engage the audience before and after the symposium by inviting hematologists to test their knowledge and compare their treatment approaches with their colleagues.
Chair:
David J. Kuter, Massachusetts General Hospital, Boston,
MA
Speakers:
Ivy Altomare
, MD
, Duke University School of Medicine
, Durham,
NC
Spero Cataland
, MD
, Ohio State University Medical Center
, Columbus,
OH
Marie Scully
, MD
, University College London Hospitals, Cardiometabolic Programme, National Institute for Health Research UCLH-UCL Biomedical Research Center
, London,
United Kingdom
Ilene C. Weitz
, MD
, University of Southern California
, Los Angeles,
CA
Contact:
Jae Eising
, Medscape Education
Email: jeising@medscape.net
Registration:
www.medscape.org/sympo/rare-heme-disorders
CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia – Clinical Updates and Innovations
This program is supported by Novartis Pharmaceuticals, Legend Biotech
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hilton Orlando
, Florida Ballroom 1-4
This interactive symposium will gather 4 experts that utilize CAR T-cell-based therapy for the treatment of patients with hematologic malignancies. They will discuss clinical data of approved and emerging CAR T-cell therapies in patients with lymphoma, myeloma, and leukemia, as well as strategies for mitigating treatment-related adverse events and improving patient outcomes. In addition to clinical data presentations, the symposium will include case reviews, panel discussions, audience Q&A, audience response technology and more. Afterwards, there will also be an associated online enduring activity, with both activities being certified for
AMA Category 1 Credit.Chair:
Julie M Vose
, MD MBA, University of Nebraska Medical Center, Omaha,
NE
Speakers:
Bruce L Levine
, PhD
, University of Pennsylvania
, Philadelphia,
PA
Frederick L. Locke
, MD
, Moffitt Cancer Center
, Tampa,
FL
David S. Siegel
, Hackensack University Medical Center
, Hackensack,
NJ
Contact:
Chloe Dunnam
, Bio Ascend
Email: dunnam@bioascend.com
Registration:
http://www.cartsymposium.com
Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies
This program is supported by Aplastic Anemia and MDS International Foundation
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Orange County Convention Center
, W308, Level 3
The Cleveland Clinic Taussig Cancer Institute and AA & MDS International Foundation join together to present the symposium,
Clinical Management of Myeloid Malignancies: The Coming of Age of Targeted Therapies. This CME-certified activity will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, AML and myeloid malignancies. The overall goal of the program is to bring together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.
Chair:
Betty K. Hamilton
, MD, Cleveland Clinic Foundation, Cleveland,
OH
Speakers:
Angela G. Fleischman
, MD, PhD
, University of California, Irvine
, Irvine,
CA
Lukasz P. Gondek
, MD,PhD
, Johns Hopkins
, Baltimore,
MD
Alan F. List
, MD
, Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute
, Tampa,
FL
Uwe Platzbecker
, MD
, University Hospital Leipzig
, Leipzig,
Germany
Phillip Scheinberg
, MD
, Hospital A Beneficencia Portuguesa
, São Paulo,
Brazil
Eytan M. Stein
, MD
, Memorial Sloan Kettering Cancer Center
, New York,
NY
Contact:
Ronna Romano
, Cleveland Clinic
Email: romanor@ccf.org
Registration:
www.ccfcme.org/wave19
Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL
This program is supported by MorphoSys AG
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Rosen Centre
, Grand Ballroom C
Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL will bring you expert perspectives on managing challenges in treating patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). You will learn about the disease continuum, including state-of-the-art approaches in risk classification and selection of therapy. Although first-line chemoimmunotherapy is the current standard of care for patients with newly diagnosed DLBCL, approximately half of the patients will experience either disease relapse or refractory disease. Stem-cell transplant plays an important role in the management of these patients; however, many patients are not candidates for transplant due to age, comorbidities, and other factors, creating an unmet medical need. In this activity, you will also learn about cutting-edge approaches in development for transplant-ineligible patients with relapsed/refractory DLBCL, including antibodies targeting novel cell-surface antigens, inhibitors of B-cell receptor signaling, and cellular immunotherapy. Throughout the program, expert discussion panels will illustrate emerging approaches for patients with relapsed/refractory DLBCL, as well as review related abstracts to be presented in Orlando.Chair:
Gilles A. Salles
, MD, PhD, Lyon-Sud University Hospital Complex, Pierre-Bénite,
France
Speakers:
Ranjana Advani
, MD
, Stanford Cancer Institute
, Stanford,
CA
Andre H. Goy
, MD, MS
, John Theurer Cancer Center at Hackensack-UMC
, Hackensack,
NJ
Marie José Kersten
, MD, PhD
, University of Amsterdam
, Amsterdam,
Netherlands
Kami J. Maddocks
, MD
, Ohio State University Hospital
, Columbus,
OH
Thomas E. Witzig
, MD
, Mayo Clinic Cancer Center
, Rochester,
MN
Contact:
Dayna Kleinstein
, Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com
Registration:
www.gotoper.com/go/DLBCL19
Expert Perspectives on the Role of BTK Inhibitors in CLL
This program is supported by Acerta Pharma - A member of the AstraZeneca Group
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Plaza International D-F
This live, case-based symposium is designed to aid community and academic hematologists/oncologists in applying clinical concepts regarding BTK inhibitors to therapeutic decision making for patients with CLL. Experts will discuss the latest clinical trial data and will offer clinical pearls about selecting patients to receive BTK inhibitors. This education will help clinicians integrate BTK inhibitors into practice and will improve their ability to tailor therapy for patients with CLL based on their individual and disease specific characteristics.Chair:
Jonathon B. Cohen
, MD,MS, Emory University, Atlanta,
GA
Speakers:
Danielle M. Brander
, MD
, Duke University Medical Center
, Durham,
NC
Philip A. Thompson
, MBBS
, The University of Texas MD Anderson Cancer Center
, Houston,
TX
Contact:
Erin Kiernan
, Medscape Education
Email: ekiernan@medscape.net
Registration:
www.medscape.org/sympo/cll-btk
Medical Crossfire®: Case Studies in AYA and Adult Acute Lymphoblastic Leukemia – How the Experts Think and Treat
This program is supported by Amgen Inc., Pfizer, Inc., and Takeda Oncology.
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Plaza International H
This Medical Crossfire® will provide an ideal format for you to participate in an open exchange of ideas and viewpoints fostered by a case-based agenda centered on the contemporary management of patients with ALL. You will have the opportunity to absorb the perspectives of leading clinical experts on a variety of different patient scenarios, and to reflect on their handling of these cases as they integrate relevant evidence into real-world practice. You will also be able to compare your patient care approaches with those of the faculty and other participating clinicians. Faculty will discuss factors that may influence risk stratification and treatment decisions, methods to best integrate the latest therapies into ALL treatment paradigms, barriers to optimized integration of these novel agents, and best practices to assist you with the management of adverse events.Chair:
Elias Jabbour, University of Texas M.D. Anderson Cancer Ctr., Houston,
TX
Speakers:
Nicola Goekbuget
, MD
, Goethe University Hospital
, Frankfurt,
Germany
Stephan Grupp
, MD, PhD
, Children's Hospital of Philadelphia
, Philadelphia,
PA
Dieter Hoelzer
, MD, PhD
, University of Frankfurt
, Frankfurt,
Germany
Hagop M. Kantarjian
, MD
, M.D. Anderson Cancer Center
, Houston,
TX
Contact:
Dayna Kleinstein
, Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com
Registration:
www.gotoper.com/go/ALL19
Minimal Residual Disease in Hematologic Malignancies: Testing Considerations and Challenges
This program is supported by Adaptive Biotechnologies and Sanofi Genzyme
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hilton Orlando
, Orlando Ballroom 3
A multi-specialty panel of experts will convene to review the role of MRD in hematologic malignancies, including prognostic factors; distinguishing among types of MRD tests; when to test; and the current understanding of the value of MRD across hematologic malignancies, including MM, ALL, CLL and AML.
Chair:
Gail J. Roboz
, MD, Weill Cornell Medicine, New York,
NY
Speakers:
Ajai Chari
, MD
, Mt. Sinai School of Medicine
, New York,
NY
Steven Coutre
, MD
, Stanford Univ. School of Med.
, Stanford,
CA
Prashant Kapoor
, MD
, Mayo Clinic
, Rochester,
MN
Aaron C. Logan
, MD, PhD
, University of California San Francisco
, San Francisco,
CA
Contact:
Kelly Jackson
, Imedex
Email: k.jackson@imedex.com
Registration:
https://www.naccme.com/program/7335
Moving Beyond Factor: Shifting the Paradigm in Hemophilia Through Gene Therapy
This program is supported by BioMarin, Spark Therapeutics and uniQure.
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Rosen Centre
, Grand Ballroom AB
Join an international panel of experts to learn the latest data and advances in the development of gene therapy for the treatment of hemophilia. Clinicians will receive guidance about the key considerations for incorporating gene therapy into patient care. Video-based patient stories will provide perspectives on the decision-making process for pursuing gene therapy as a treatment option and the impact on the patient's daily life.
Chair:
Steven Pipe
, MD, University of Michigan, Ann Arbor,
MI
Speakers:
Wolfgang Miesbach
, MD, PhD
, Goethe University Hospital
, Frankfurt/Main,
Germany
John Pasi
, MB, ChB, PhD, FRCP, FRCPath, FRCPCH
, Barts and the London School of Medicine and Dentistry
, London,
United Kingdom
Thierry VandenDriessche
, PhD
, Vrije University Brussels
, Brussels,
Belgium
Contact:
Charlene Foroutan
, Medscape Oncology
Email: cforoutan@medscape.net
Registration:
www.medscape.org/sympo/gene-therapy-hemophilia
New Data and Paradigms in ALL: Insights and Applications
This program is supported by Servier
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Plaza International I-K
This interactive symposium is designed to improve the knowledge and confidence of haematologists/oncologists in applying best practice in the treatment of ALL. The faculty will describe and discuss the very latest data and thinking in the treatment of ALL across the full spectrum of age groups encountered in practice: pediatrics, adolescents/young adults and adults. Specific attention will be placed on discussing the role of asparaginase in treatment protocols in terms of selection and optimal application in practice, including anticipation and appropriate management of asparaginase toxicities and hypersensitivity/silent inactivation. A key overall goal is to address how clinicians can improve on the current treatment of ALL to achieve the best outcomes for patients.
Chair:
Daniel J. DeAngelo, Harvard Medical School, Boston,
MA
Speakers:
Dan Douer
, MD
, University of Southern California
, Los Angeles,
Lewis B. Silverman
, MD
, Dana-Farber Cancer Institute
, Boston,
MA
Wendy Stock
, MD
, University of Chicago
, Chicago,
IL
Contact:
Erin Kiernan
, Medscape Education
Email: ekiernan@medscape.net
Registration:
www.medscape.org/sympo/all-evolvingtreatment
New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Case Discussions
This program is supported by Seattle Genetics and Takeda Oncology
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Regency S
This satellite symposium presents a great opportunity for clinicians to learn about the latest therapeutic advances in peripheral T-cell lymphoma (PTCL). Prior to the live event, this program will include 2 online expert commentaries on the evolving PTCL treatment landscape. At the live symposium, the faculty will review recent advances in PTCL treatment, including biomarker assessment, chemotherapy-based frontline treatments, novel targeted agents, combination therapies, treatment options in the relapsed/refractory (R/R) setting, and provide guidance on individualized therapeutic approaches. A moderated panel discussion and an audience question and answer session will close each section of the symposium and will provide further perspectives on how the experts interpret the available clinical data and apply them in their practice. Symposium participants will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and contribute to the cases discussed by the panel. Throughout the symposium, participants will have the opportunity to directly query the faculty for further clarification of the education or to obtain expert perspectives on their own treatment challenges.
Chair:
Steven M. Horwitz
, MD, Memorial Sloan Kettering Cancer Center, New York,
NY
Speakers:
Francine M. Foss
, MD
, Yale University School of Medicine
, New Haven,
CT
Barbara Pro
, MD
, Feinberg School of Medicine, Northwestern University
, Chicago,
IL
Contact:
For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com
Registration:
http://www.clinicaloptions.com/2019OrlandoPTCL
Potentiating the Power of Platelets: Examining the Clinical Utility of Multiple Thrombopoietin Receptor Agonists in ITP, Chemotherapy Induced Thrombocytopenia and Liver Disease
This program is supported by Dova Pharmaceuticals
Friday, December 06, 2019,
12:30 p.m. - 3:00 p.m.
Hilton Orlando
, Orlando Ballroom 4-6
Advances in understanding the pathophysiology of thrombocytopenia have led to the development of a new class of agent, thrombopoietin receptor agonists (TRAs), two of which were recently approved by the US Food and Drug Administration. These therapies have implications across a range of thrombocytopenias and disease states. TRAs overcome many limitations of the minimally effective conventional procedures used to manage patients with chronic liver disease who undergo elective surgical procedures. TRAs also have implications as first- and second-line treatment strategies in patients with chronic thrombocytopenia, specifically immune thrombocytopenia purpura (ITP), and is emerging as a treatment strategy for chemotherapy-induced thrombocytopenia. Appropriate use of these agents in practice requires that treating clinicians are both up-to-date on the latest evidence-based literature regarding TRAs as part of thrombocytopenia management and proficient in implementing these treatments appropriately. As a result, there is a need for education, specifically for hematologists and other healthcare professionals who treat patients with thrombocytopenia, that focuses on the efficacy and safety of novel treatments, the pathophysiology of hemostatic mechanisms affected in liver disease and other pathologies, bleeding risk laboratory measures used to guide treatment-making decisions, and navigating guideline recommendations for the appropriate diagnosis and treatment strategies for patients with thrombocytopenia.
Chair:
Satish Pramod Shanbhag
, MBBS, MPH, Johns Hopkins University School of Medicine, Baltimore,
MD
Speaker:
James B. Bussel
, MD
, Weill Cornell Medicine
, New York,
NY
Contact:
Catherine Zehr
, ASiM CE LLC
Email: czehr@asimcme.com
Registration:
http://www.jhasim1.com/index.aspx?case_ID=806
Primary HLH: Diagnosis, Management, and Treatment in the 21st Century
This program is supported by Swedish Orphan Biovitrum AB
Friday, December 06, 2019,
12:30 p.m. - 3:30 p.m.
Rosen Centre
, Grand Ballroom DE
Hemophagocytic lymphohistiocytosis (HLH) is a rare blood disorder mediated by overactivated immune cells. Rare hematologic disorders present a distinct challenge for hematologists and other physicians, and prompt differential diagnosis and initiation of effective treatment are critical to optimizing outcomes for patients with HLH. This satellite symposium will provide physicians who encounter these patients with up-to-date information on the diagnosis, pathobiology, and treatment of primary HLH. The expert faculty panel will review the latest clinical data and ongoing clinical trials with the potential to affect care of patients with HLH. Didactic presentations combined with illustrated case studies will provide the opportunity to apply new information to clinical scenarios, equipping participants with the tools to utilize emerging data to optimize care of their patients with HLH.Chair:
Michelle L. Hermiston
, MD, PhD, University of California San Francisco, Benioff Children's Hospital, San Francisco,
CA
Speakers:
Ashish R Kumar
, MD, PhD
, Cincinnati Children's Hospital Medical Center
, Cincinnati,
OH
Kenneth L. McClain
, MD, PhD
, Texas Childrens Cancer and Hematology Centers
, Houston,
TX
Philip A. Roehrs
, MD
, Carolinas Medical Center
, Charlotte,
NC
Contact:
Dayna Kleinstein
, Physicians' Education Resource, LLC (PER)
Email: info@gotoper.com
Registration:
www.gotoper.com/go/HLH19
Relapsed/Refractory Multiple Myeloma: Current Treatment and Emerging Approaches
This program is supported by GlaxoSmithKline, Oncopeptides and Karyopharm Therapeutics.
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Orlando Ballroom LMN
This live symposium is designed to improve the knowledge of hematologists/oncologists about the evolving multiple myeloma treatment paradigm. Case-based discussion will provide clinical pearls about how to tailor therapy selections for patients with first relapse and multiply relapsed disease. Novel and emerging therapies will also be discussed so providers can effectively integrate these agents into practice when they become available.Chair:
Ravi Vij
, MBBS, Washington University School of Medicine at St. Louis, Ballwin,
MO
Speakers:
Christina Gasparetto
, MD
, Duke Cancer Institute
, Durham,
NC
Peter M. Voorhees
, MD
, Levine Cancer Institute - Morehead (Hematology)
, Charlotte,
NC
Contact:
Charlene Foroutan
, Medscape Oncology
Email: cforoutan@medscape.net
Registration:
www.medscape.org/sympo/emerging-myeloma
ß-Thalassemia: Expert Insights on New Therapies for an Old Disease
This program is supported by Celgene Corporation
Friday, December 06, 2019,
12:30 p.m. - 4:30 p.m.
Hyatt Regency Orlando
, Regency R
This live, CME-certified symposium will reveal how experts approach current therapeutic decisions for their patients with ß-thalassemia and provide a look ahead at new data and promising agents that may soon change practice.
International ß-thalassemia experts—Maria Domenica Cappellini, MD; Janet L. Kwiatkowski, MD, MSCE; and Sujit Sheth, MD—will discuss evidence behind current best practice management strategies for both transfusion-dependent thalassemia (TDT) and non-TDT, including patient case presentations, their treatment recommendations for each case, and reflection on challenges that impact therapeutic decisions. Recent clinical trial evidence and ongoing clinical trials on novel therapeutic approaches, including erythroid maturation agents and gene therapy with lentiviral vectors, will be presented and discussed, with a focus on how these agents may affect management strategies for patients with ß-thalassemia in the near future.
Throughout the symposium, attendees will interact with the experts through case-based challenges and polling questions as well as will be able to text questions directly to the panel for their consideration.
Discussion topics include:
-Overview of ß-Thalassemia and Unmet Therapeutic Needs
-Current Management of ß-Thalassemia
-Emerging Biologic Therapies on the Horizon
-The Promise of Gene Therapy in ß-Thalassemia
Chair:
Maria Domenica Cappellini
, MD, Foundation IRCCS Ca' Granda Policlinico Milano - University of Milan, Milano,
MI, Italy
Speakers:
Janet L. Kwiatkowski
, MD, MSCE
, The Children's Hospital of Philadelphia
, Philadelphia,
PA
Sujit Sheth
, MD
, Cornell University
, New York,
NY
Contact:
For help with registering, please call
1-855-224-2241 (9:00 AM – 5:00 PM Eastern, weekdays)
Email: meetings@clinicaloptions.com
Registration:
http://www.clinicaloptions.com/2019OrlandoBetaT